Compare ING Groep NV (ING) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ING Groep NV vs Zimmer Biomet Holdings Inc — how do they compare? ING Groep NV trades at $35.51 (market cap $101.22B), while Zimmer Biomet Holdings Inc trades at $95.7 (market cap $18.55B). The key difference: ING Groep NV is far larger — about 5.5× Zimmer Biomet Holdings Inc's market cap, and ING Groep NV pays the higher dividend (3.73%). Which is the better fit depends on your goals.
| ING | ZBH | |
|---|---|---|
Market Cap | $101.22B | $18.55B |
Sector | Financials | Health |
52-Week High | $35.92 | $107.71 |
52-Week Low | $23.66 | $79.58 |
Dividend Yield | 3.73% | 0.99% |
Enterprise Value | — | $25.61B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ING trades at $35.24, down 1.23% today, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $0.79, and raised its full-year revenue guidance. Analyst consensus is strongly positive with 62.5% buy ratings. Recent news highlights strategic acquisitions and a dividend payment scheduled for August 2026.
The outlook for ING is favorable, supported by earnings momentum and upward guidance revisions. Key opportunities include growth in net interest income and fee-based revenue. Risks involve persistent negative operating cash flows and sensitivity to European economic conditions. The stock presents a value proposition with a P/E of 13.24, though cash flow trends warrant monitoring.
ZBH trades at $97.78, up 1.27% today, with a bullish technical outlook supported by moving averages and recent earnings beats. The company reported Q2 2026 EPS of $2.07, exceeding expectations, and raised its 2026 outlook. Revenue growth remains steady at 4.8% year-over-year, though net income margin has moderated from 2023 peaks. Analyst consensus is a 'Buy' with a $103.56 price target, indicating modest upside potential from current levels.
The stock offers a balanced risk-reward profile with solid fundamentals and positive momentum, but faces headwinds from margin pressure and rising debt levels. Investors should weigh the strong institutional support and consistent earnings performance against competitive pressures and macroeconomic uncertainties affecting the medtech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ING Groep NV
The merger of the Dutch postal bank and NN Insurance in 1991 created ING. Through a series of further acquisitions ING build up a global footprint. The 2008 financial crisis forced ING to seek government support--a precondition of which was that ING should separate its banking and insurance activities, which saw ING revert to being solely a bank. ING has market- leading banking operations in the Netherlands and Belgium, and a range of digital banks across Europe and Australia. Its global wholesale banking operation is primarily focused on lending.
Read more on ING →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
